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Sigma-2 ligands induce tumour cell death by multiple
signalling pathways
C Zeng1, J Rothfuss1, J Zhang1, W Chu1, S Vangveravong1, Z Tu1, F Pan1, KC Chang2, R Hotchkiss2
and RH Mach*,1,3,4

BACKGROUND: The sigma-2 receptor has been identified as a biomarker of proliferating cells in solid tumours. In the present study,
we studied the mechanisms of sigma-2 ligand-induced cell death in the mouse breast cancer cell line EMT-6 and the human
melanoma cell line MDA-MB-435.
METHODS: EMT-6 and MDA-MB-435 cells were treated with sigma-2 ligands. The modulation of multiple signaling pathways of cell
death was evaluated.
RESULTS: Three sigma-2 ligands (WC-26, SV119 and RHM-138) induced DNA fragmentation, caspase-3 activation and PARP-1
cleavage. The caspase inhibitor Z-VAD-FMK partially blocked DNA fragmentation and cytotoxicity caused by these compounds.
These data suggest that sigma-2 ligand-induced apoptosis and caspase activation are partially responsible for the cell death. WC-26
and siramesine induced formation of vacuoles in the cells. WC-26, SV119, RHM-138 and siramesine increased the synthesis and
processing of microtubule-associated protein light chain 3, an autophagosome marker, and decreased the expression levels of the
downstream effectors of mammalian target of rapamycin (mTOR), p70S6K and 4EBP1, suggesting that sigma-2 ligands induce
autophagy, probably by inhibition of the mTOR pathway. All four sigma-2 ligands decreased the expression of cyclin D1 in a timedependent manner. In addition, WC-26 and SV119 mainly decreased cyclin B1, E2 and phosphorylation of retinoblastoma protein
(pRb); RHM-138 mainly decreased cyclin E2; and 10 mM siramesine mainly decreased cyclin B1 and pRb. These data suggest that
sigma-2 ligands also impair cell-cycle progression in multiple phases of the cell cycle.
CONCLUSION: Sigma-2 ligands induce cell death by multiple signalling pathways.
British Journal of Cancer (2012) 106, 693 – 701. doi:10.1038/bjc.2011.602 www.bjcancer.com
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Sigma receptors are a distinct class of receptors that are found in
many tumours and normal tissues. Sigma receptors have been
associated with many cellular and organ processes, including
motor function, endocrine function, proliferation, immunoregulation and ion channel modulation (Walker et al, 1990; Hellewell
et al, 1994; Megalizzi et al, 2010). Radioligand binding studies and
biochemical analyses have shown that there are at least two types
of sigma receptors, sigma-1 (B25 kDa) and sigma-2 (B21.5 kDa).
The sigma-1 receptor has been cloned from many species (Hanner
et al, 1996; Seth et al, 1997). Recently the progesterone receptor
membrane component 1 (PGRMC1) protein complex was identified as the putative sigma-2 receptor-binding site (Xu et al, 2011).
Sigma-2 receptors are expressed in high density in nearly all
human and rodent tumour cell lines (Vilner et al, 1995). Sigma-2
receptor densities have been correlated with the grade of some
human and bovine tumours (Bem et al, 1991; Colabufo et al, 2006;
Roperto et al, 2010). The density of sigma-2 receptors in proli*Correspondence: Dr RH Mach; E-mail: rhmach@mir.wustl.edu
Revised 27 October 2011; accepted 19 December 2011; published
online 17 January 2012

ferating mouse mammary adenocarcinoma cells was found to be
B10-fold higher than that in the corresponding quiescent tumour
cells both in vitro and in vivo (Mach et al, 1997; Wheeler et al, 2000).
These observations have led to the development of the sigma-2
ligands as molecular probes for diagnostic imaging of solid tumours
(Wheeler et al, 2000; Mach et al, 2001a; Kawamura et al, 2003),
and the identification of sigma-2 receptors as a potential target for
treatment of cancer (John et al, 1998; Caveliers et al, 2001).
Apoptosis (programmed cell death) is a physiological process that
is important for development, homeostasis and suppression of
oncogenesis (Jacobson et al, 1997). Deregulated apoptosis has been
implicated in many diseases, including ischemic stroke and cancer
(Reed, 2002). It is well known that the caspase family has a central
role in both the intrinsic and extrinsic pathways of apoptosis.
Caspase-3, the ‘executioner’ caspase, is a key enzyme, which
degrades proteins such as gelsolin and lamin, leading to apoptotic
cell death (Reed, 2002). Sigma-2 ligands with different chemical
structures have been reported to induce apoptosis in several tumour
cell lines (Brent et al, 1996; Crawford and Bowen, 2002; Crawford
et al, 2002, 2003; Barbieri et al, 2003; Ostenfeld et al, 2005; Cassano
et al, 2009). Although two of these studies (Crawford and Bowen,
2002; Ostenfeld et al, 2005) have shown that prolonged exposure to

Translational Therapeutics

1
Department of Radiology, Division of Radiological Sciences, Washington University School of Medicine, 510 S Kingshighway Boulevard, St Louis,
MO 63110, USA; 2Department of Anesthesiology, Washington University School of Medicine, 510 S Kingshighway Boulevard, St Louis, MO 63110, USA;
3
Department of Cell Biology and Physiology, Washington University School of Medicine, 510 S Kingshighway Boulevard, St Louis, MO 63110, USA;
4
Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, 510 S Kingshighway Boulevard, St Louis, MO 63110, USA

Sigma-2 ligands induce tumour cell death
C Zeng et al

694

Translational Therapeutics

sigma-2 ligands kills cancer cells by a caspase-independent apoptotic
pathway, a complete understanding of how sigma-2-selective ligands
induce cell death has not yet been established.
Autophagy is a lysosomal degradation pathway for cytoplasmic
materials (Glick et al, 2010). At basal levels, autophagy maintains
cellular homeostasis by removing misfolded or aggregated
proteins, and by clearing damaged cellular organelles. Autophagy
is strongly induced upon nutrient deprivation and enhances cell
survival by degrading nonessential components of the cell to
generate nutrients for vital biological processes. Autophagy begins
with an isolation membrane, also known as a phagophore. The
phagophore then expands to engulf cytoplasmic materials, forming
a closed double-membrane autophagosome. Autophagosomes fuse
with endosomal and/or lysosomal vesicles, promoting degradation
of autophagosomal contents by lysosomal acid proteases.
The degradation products can be re-used for cellular metabolism.
By contrast, excessive autophagy can result in non-apoptotic cell
death (Platini et al, 2010). Mammalian target of rapamycin
(mTOR) promotes cell growth and inhibits autophagy (Janku
et al, 2011). Mammalian target of rapamycin kinase forms two
distinct multiprotein complexes called mTORC1 and mTORC2.
Mammalian target of rapamycin-C1 activity results in phosphorylation of S6 ribosomal protein kinase (S6K), phosphorylation of
eukaryotic initiation factor 4E-binding protein (4EBP1) and
subsequent activation of the protein translational machinery in
the cell. Mammalian target of rapamycin-C2 mediates Akt
activation, which in turn stimulates and activates mTORC1.
Because of its dual role in cell survival and cell death, both
inhibition and activation of the autophagic lysosomal pathway are
novel strategies for treating cancer (Platini et al, 2010). In fact,
Ostenfeld et al (2008) have proposed combination therapy of
siramesine, a sigma-2 ligand, with drugs that inhibit autophagy as
a strategy for treating cancer.
The cell cycle can be described by four successive cellular phases:
a phase of cell growth to prepare for DNA replication (G1), a phase
of DNA synthesis and replication (S), and a phase of cell growth and
active synthesis of factors (G2) required for mitosis (M) (Malumbres
and Barbacid, 2009). Progression through the cell cycle is regulated
by sequential waves of different cyclin/cyclin-dependent kinase (CDK)
activities. Cyclins are synthesised and destroyed at specific time points
during the cell cycle, thus regulating CDK kinase activities in a timely
manner. Cyclin-dependent kinase–cyclin complexes directly involved
in cell-cycle control include three interphase CDKs (CDK2, CDK4 and
CDK6), a mitotic CDK (CDK1) and four classes of cyclins (cyclins A,
B, D and E). Mitogenic signals first induced the expression of D-type
cyclins (D1, D2 and D3). The D-type cyclins bind to and activate
CDK4 and CDK6 during G1 phase, leading to phosphorylation of the
retinoblastoma protein (Rb). Phosphorylation of Rb releases the E2F
transcription factors, which can then activate genes essential for G1 –S
transition and S-phase, including E-type cyclins (Witzel et al, 2010).
The E-type cyclins are required to activate Cdk2 for proper completion
of the G1 phase, as well as for initiating DNA replication. Once cells
enter S-phase, Cdk2–cyclin E complexes need to be silenced to avoid
re-replication of DNA. The A-type cyclins accumulate during S-phase.
Cyclin-dependent kinase-2–cyclin A complexes have been reported
to phosphorylate numerous proteins that are required for proper
completion and exit from S-phase. During G2, the A-type cyclins
are degraded by ubiquitin-mediated proteolysis whereas the B-type
cyclins are actively synthesised. As a consequence, Cdk1 binds to
the B-type cyclins – an association believed to regulate several events
during both the G2 – M transition and progression through mitosis.
Finally, inactivation of Cdk1 – cyclin B complexes is required for
proper exit from mitosis. This inactivation is accomplished by
degradation of the B-type cyclins through the proteolytic pathway
mediated by ubiquitination. Cell-cycle malfunction may cause cell
death (Allan and Clarke, 2008; Clarke and Allan, 2009). Recent results
indicate that regulation of apoptosis is directly linked with cell-cycle
checkpoints by common components (Clarke and Allan, 2009).
British Journal of Cancer (2012) 106(4), 693 – 701

Few studies have investigated the effects of sigma-2 ligands on the
cell cycle.
Our group has previously reported the synthesis and in vitro
characterisation of a number of structurally diverse ligands with a
high affinity for sigma-2 receptors (Mach et al, 2001b, 2003, 2004).
By screening these sigma ligands for their cytotoxicity, we
identified three potent sigma-2-selective ligands, WC-26, SV119
and RHM-138, that killed mouse breast cancer EMT-6 and human
MDA-MB-435 melanoma tumour cells with EC50s in micromolar
range after a 48-h exposure. The aim of the present study was to
explore the mechanism by which these three sigma-2-selective
ligands induce cell death. The data presented in this report indicate
that treatment of EMT-6 and MDA-MB-435 cancer cells with these
sigma-2 ligands induces multiple mechanisms of cell death,
including apoptosis, autophagy and cell-cycle impairment.

MATERIALS AND METHODS
Cell culture conditions
EMT-6 mouse breast cancer cells were grown in DMEM containing
10% fetal bovine serum, 100 U ml1 penicillin and 100 mg ml1
streptomycin. MDA-MB-435 human melanoma cells were grown in
MEM containing 10% fetal bovine serum, 2 mM L-glutamine, 1 mM
sodium pyruvate, 1% nonessential amino acids (Mediatech Inc.,
Manassas, VA, USA), 2% MEM vitamins (Invitrogen, Carlsbad,
CA, USA), 100 U ml1 penicillin and 100 mg ml1 streptomycin.
Both cell lines were maintained at 37 1C in a humidified incubator
under a 5% CO2/95% air atmosphere.

MTS assay
The cytotoxicity of sigma-2 ligands was determined using the
CellTiter96 Aqueous One Solution (Promega, Madison, WI, USA),
which contains a tetrazolium compound (3-(4,5-dimethylthiazol2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazo
lium, inner salt; MTS).

LDH assay
Lactate dehydrogenase (LDH) release assay was performed using
the Cytotox 96 Non-Radioactive Cytotoxicity Assay (Promega)
according to the manufacturer’s protocol.

Detection of intracellular caspase-3 activity
Activation of endogenous caspase-3 by sigma ligands was
measured using the CellProbe HT caspase-3 whole-cell assay
(Beckman Coulter, Fullerton, CA, USA) (see Supplementary
Information for description of caspase-3 assay).

Flow cytometry
Flow cytometric analysis was performed using a FACScan (Becton
Dickinson, Fullerton, CA, USA) equipped with an air-cooled argon
laser. TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end
labelling)-positive cells were detected with FITC–dUTP and quantified
by flow cytometry using a TUNEL assay according to the manufacturer’s protocol (Apo-direct Kit; BD Biosciences Pharmingen,
San Diego, CA, USA). Briefly, the cells were detached from the
culture dishes with trypsin, washed with phosphate-buffered saline
(PBS) and then fixed in 1% paraformaldehyde. After washing with
PBS twice, the cells were incubated with a DNA labelling solution
containing terminal deoxynucleotidyl transferase and FITC – dUTP
at 37 1C for 1 h. After washing with PBS, 7-amino-actinomycin D
(7-AAD; BD Biosciences Pharmingen) was added to the cells to
stain the nucleic acid at a concentration of 5 ml (0.25 mg) 7-AAD/
test (1  106 cells). The cells were then analysed by flow cytometry.
& 2012 Cancer Research UK
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treated with 100 mM WC-26 or 10 mM siramesine for 0, 4, 8 and 16 h.
The cells were quickly rinsed with PBS twice at room temperature
and then fixed with 1 ml of 2.5% glutaraldehyde in 0.01 M Na
cacodylate buffer at 4 1C until use. After rinsing with PBS, fixed
cells were sequentially stained with osmium tetroxide and uranyl
acetate, and then dehydrated and embedded in overturned gelatin
capsules containing Polybed 812 resin (Polysciences, Warrington,
PA, USA). The resin blocks were thin sectioned at 90 – 100 nm on a
Reichert-Jung Ultracut microtome, post-stained in uranyl acetate
and lead citrate, viewed on a Zeiss 902 Electron Microscope,
and recorded with Kodak EM film.

Fluorescein isothiocyanate was excited at 488 nm and emission was
collected with a 570-nm filter. 7-Amino-actinomycin D was excited at
488 nm and emission was collected using a 650-nm long-pass filter.

Western blot analysis
EMT-6 cells (2  105) or MDA-MB-435 cells (4  105) were plated
in 100-mm culture dishes 24 h prior to treatment with the sigma-2selective ligands. For detection of caspase-3 activation, the
cells were treated with WC-26 (40 mM for EMT-6, 80 mM for
MDA-MB-435), SV119 (100 mM) or RHM-138 (40 mM). For detection
of autophagy and cell-cycle impairment, MDA-MB-435 cells were
treated with WC-26 (100 mM), SV119 (100 mM), RHM-138 (40 mM) or
siramesine (10 mM). At various time points, cells were harvested
and cell lysates were prepared using CHAPS buffer (50 mM Pipes/
HCl (pH 6.5), 2 mM EDTA, 0.1% CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-propane sulphonate), 20 mg ml1 leupeptin,
10 mg ml1 pepstatin A and 10 mg ml1 aprotinin). Aliquots of
protein (30 mg) from each sample were analysed using standard
immunoblotting procedures. Rabbit antibodies of caspase-3,
PARP-1, LC3B, cyclin B1, cyclin D1, cyclin E2, pRb (Ser780),
phospho-p70S6K (Thr389) and phospho-4EBP1 (Thr37/46), and a
mouse antibody of cyclin A were purchased from Cell Signaling
Technology (Danvers, MA, USA). All primary antibodies were used
at a 1 : 1000 dilution. The secondary antibody was horseradish
peroxidase (HRP)-conjugated goat anti-rabbit IgG or HRP-conjugated
horse anti-mouse IgG (Cell Signaling Technology) at a 1 : 3000 or
1 : 10 000 dilution, respectively. The SuperSignal WestDura Extended
Duration Substrate assay kit (Pierce Biotechnology Inc., Rockford,
IL, USA) was used to detect the secondary antibody. For stripping
western blots, the blot was incubated with stripping buffer (Pierce
Biotechnology Inc.) for 15 min at room temperature.

Statistical analysis

RESULTS
Sigma-2 ligands induced cytotoxicity
The chemical structures of the four sigma-2 ligands are shown in
Figure 1A. Using the MTS assay, dose – response curves were
generated after exposing EMT-6 and MDA-MB-435 cells
to increasing concentrations of WC-26, SV119, RHM-138 and
siramesine for 24 or 48 h. Cell kill increased with increasing dose of
and exposure time to the four sigma-2 ligands (Figure 1B).
All EC50s were in the micromolar range (Table 1).

Sigma-2 ligands induced caspase-3 activation
Transmission electron microscopy

To assess if caspase-mediated apoptosis was involved in the
cytotoxic pathway, caspase-3 activity was measured by a whole-cell
assay described under Materials and Methods. The EMT-6 cells

MDA-MB-435 cells were plated in a 35-mm cell culture dish at a
cell density of 3.2  105 cells per dish for 24 h. The cells were then
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Figure 1 Sigma-2 ligands decreased viability in EMT-6 and MDA-MB-435 cells. (A) Chemical structures of the sigma-2 ligands. (B) EMT-6 or MDA-MB435 cells were treated with increasing concentrations of the sigma-2 ligands WC-26, SV119, RHM-138 and siramesine for 48 h. Cell viability was determined
by MTS assay. The bars represent the mean±s.e.m. of at least three independent experiments.
& 2012 Cancer Research UK
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The results are expressed as the mean±s.d. based on three
independent experiments performed in triplicate. Differences
among groups were statistically analysed by two-tailed Student’s
t-test. A P-value of o0.05 was considered significant.
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Table 1

Cytotoxicity of sigma-2 ligands

Compound

EMT-6
EC50 (lM, 24 h)

EMT-6
EC50 (lM, 48 h)

MDA-MB-435
EC50 (lM, 24 h)

MDA-MB-435
EC50 (lM, 48 h)

42.5±3.5
16.0±1.4
32.5±3.5

12.3±1.6
11.4±1.7
19.5±2.0
5.3±1.0

49.7±2.5
36.7±3.33
26.7±4.25

42.6±2.3
18.5±1.9
17.8±1.6
9.3±0.9

WC-26
SV119
RHM-138
Siramesine
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WC-26
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Relative caspase-3 activity
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Figure 2 Sigma-2 ligands induced caspase-3 activation. (A) EMT-6 and MDA-MB-435 cells were treated for 24 h with the sigma-2 ligands at
concentrations that resulted in the highest level of caspase-3 activation (40 mM WC-26, 40 mM SV119 or 40 mM RHM-138 for EMT-6 cells; 80 mM WC-26,
80 mM SV119 or 50 mM RHM-138 for MDA-MB-435 cells). Caspase-3 activation was determined by the CellProbe HT caspase-3 whole-cell assay. *Po0.001
compared with untreated control. The bars indicate the mean±s.d. of the representative data of at least three independent experiments. (B and C) Sigma-2
ligands induced procaspase-3 and PARP-1 cleavage as shown by western blot analysis in EMT-6 cells (B) and MDA-MB-435 cells (C). EMT-6 cells were treated
for 0 – 24 h prior to assay with WC-26 (40 mM), SV119 (100 mM) or RHM-138 (40 mM). MDA-MB-435 cells were treated for 0 – 24 h with WC-26 (80 mM),
SV119 (100 mM) or RHM-138 (40 mM).

were treated with 40 mM WC-26, 40 mM SV119 or 40 mM RHM-138
for 24 h. The data showed that caspase-3 activation in treated cells
increased by 7-, 2.5- and 2.5-fold, respectively, over activation
measured in untreated control cells (Figure 2A). MDA-MB-435
cells were also treated for 24 h with 80 mM WC-26, 80 mM SV119 or
50 mM RHM-138, and caspase-3 activities were shown to increase
by 4.5-, 3.5- and 3-fold, respectively (Figure 2A).
Caspase-3 activation was also demonstrated by western blot
analysis. Activation of caspase-3 requires proteolytic processing of
inactive procaspase-3 (35 kDa) into inactive 19-kDa and active
17-kDa, and 12-kDa caspase-3, fragments. EMT-6 (Figure 2B) and
MDA-MB-435 cells (Figure 2C) were treated for 0 – 24 h prior to the
assay. All three sigma-2 ligands induced procaspase-3 cleavage in
both EMT-6 and MDA-MB-435 cells after an 8- to 24-h treatment.
Poly(ADP-ribose) polymerase-1 (PARP-1), the 116-kDa poly(ADPribose) polymerase, is one of the main cleavage targets of caspase-3
in vivo. The western blot analyses demonstrated that all three
sigma-2 ligands induced PARP-1 cleavage in both cell lines (Figure
2B and C). Collectively, these data indicate that our three sigma-2
ligands induced cell death through an apoptotic pathway.
To determine whether caspases are responsible for the sigma-2
ligand-induced apoptosis and cell viability, the broad-spectrum
caspase inhibitor, Z-VAD-FMK, was added to the culture medium
1 h before sigma-2 ligands. The effect of this inhibitor on sigma-2
ligand-induced DNA fragmentation was determined by TUNEL
staining. The effect of the inhibitor on cell viability following
treatment with sigma-2 ligands was determined by MTS assay and
LDH assay. The results showed that DNA fragmentation induced
by each of the three sigma-2 ligands was partially blocked by
Z-VAD-FMK (100 mM) in EMT-6 cells (Figure 3A). The decreased
cell viability by the sigma-2 ligands was partially rescued by
British Journal of Cancer (2012) 106(4), 693 – 701

Z-VAD-FMK (Figure 3B and C). These data suggest that caspase
activation, to a certain extent, has a role in sigma-2 ligand-induced
cell death. It is worth noting that Z-VAD-FMK partially blocked
cell death induced by 20 mM siramesine but not by 10 mM
siramesine (Figure 3B), suggesting that the role of caspase in
sigma-2 ligand-induced cell death is concentration-dependent.

Sigma-2 ligands induced autophagy
Excess levels of autophagy may be responsible for cell death
(Platini et al, 2010). We therefore examined whether autophagy
was involved in sigma-2 ligand-induced cell death. We first used
transmission electron microscopy to examine the ultrastructure of
MDA-MB-435 cells after treatment with 100 mM WC-26 or 10 mM
siramesine. Compared with control cells (Figure 4A), 4-h treatment
with 100 mM WC-26, the earliest time point examined, induced
mitochondrial swelling (Figure 4B, structure indicated by 1) and
multilayer membrane structures (Figure 4B, structures indicated
by 2 and 3). Typical autophagy compartments, which have double
membranes and partially degraded cytoplasmic material, were
occasionally observed (Figure 4C, structure 1). Siramesine at 10 mM
also induced autophagy-like vacuoles (Figure 4D). These ultrastructures suggest that autophagy may be induced by sigma-2
ligands. We further used western blot analysis to examine the
processing of microtubule-associated protein light chain 3 (LC3),
an autophagosome marker. Light chain 3 is expressed in most cell
types as a full-length cytosolic protein, which exists in three
isoforms (LC3A, LC3B and LC3C) and is proteolytically cleaved
upon induction of autophagy, generating LC3-I. The carboxyterminal glycine of LC3-I then conjugates to phosphatidylethanolamine to generate processed LC3-II. Light chain 3-II is found on
& 2012 Cancer Research UK
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sigma-2 ligands, suggesting that the mTOR pathway is inhibited by
sigma-2 ligands, which may in turn trigger autophagy (Figure 5).
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Deregulation of cell-cycle progression may cause cell death (Allan
and Clarke, 2008; Clarke and Allan, 2009). Therefore, we examined
the effects of sigma-2 ligands on the expression levels of all four
major classes of cyclins (cyclin D1, E2, A and B1) and on the
phosphorylation levels of Rb by western blot analysis. MDA-MB435 cells were treated with 100 mM WC-26, 100 mM SV119, 40 mM
RHM-138 or 10 mM siramesine for 0, 1, 2, 4, 8, 16 and 24 h. The data
showed that all four sigma-2 ligands decreased the expression
levels of cyclin D1 in a time-dependent manner (Figure 6).
In addition, the data showed that 100 mM WC-26 or 100 mM SV119
mainly decreased cyclin B1, E2 and phospho-Rb (pRb); 40 mM
RHM-138 mainly decreased cyclin E2; and 10 mM siramesine
mainly decreased cyclin B1 and pRb. It is well known that
D-type cyclins are responsible for progression through G1 phase;
E-type cyclins for completion of G1 phase and entry into S-phase;
A-type cyclins for driving the transition from S-phase to M-phase
(G2 phase); and B-type cyclins for cell progression through
M-phase (Malumbres and Barbacid, 2009). Our data suggest that
all four sigma-2 ligands may block G1-phase progression by
decreasing cyclin D1 expression. In addition, WC-26 and SV119
may block cell entry from G1 to S-phase by decreasing cyclin E2,
and block mitosis by decreasing cyclin B1; RHM-138 may block
cell entry from G1 to S phase by decreasing cyclin E2; and
siramesine may block mitosis by decreasing cyclin B1. Collectively,
our data suggest that all four sigma-2 ligands may impair the cell
cycle in multiple phases (G1, S, G2 and M), which may lead to
apoptosis either directly or indirectly, as discussed below.
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Figure 3 The broad-spectrum caspase inhibitor, Z-VAD-FMK, partially
blocked DNA fragmentation, viability and cytotoxicity induced by sigma-2
ligands. (A) EMT-6 cells were pre-treated for 1 h with Z-VAD-FMK
(100 mM), and then treated with WC-26 (40 mM) for 48 h, SV119 (100 mM)
for 16 h or RHM-138 (40 mM) for 16 h. The percentage of TUNEL-positive
cells was analysed by flow cytometry (*Pp0.001 compared with the no
inhibitor control). (B and C) MDA-MB-435 cells were pre-treated for 1 h
with Z-VAD-FMK (100 mM), and then treated with WC-26 (100 mM),
SV119 (100 mM), RHM-138 (100 mM) or siramesine (10 or 20 mM) for 18 h.
Viability of the cells was measured by MTS assay (B). Cytotoxicity to the
cells was measured by LDH assay. (*Po0.05 compared with the no
inhibitor control). The bars represent the mean±s.d. of the representative
data of at least three independent experiments.

autophagosomes, where it has a role in both membrane fusion and
selection of cargo for degradation (Barth et al, 2010). Western blot
analysis demonstrated that LC3B-II was induced by all four sigma2 ligands (100 mM WC-26, 100 mM SV119, 40 mM RHM-138 and
10 mM siramesine) over a 24-h period (Figure 5). We also tested
whether the mTOR signalling pathway is involved in sigma-2
ligand-induced autophagy. Western blot analysis showed that
phosphorylation of p70S60 kinase and 4EBP-1, both of which are
downstream effectors of mTORC1, were decreased by all four
& 2012 Cancer Research UK

DISCUSSION
We studied the cell death mechanisms of three sigma-2 receptor
ligands developed in our group and compared the results with the
known sigma-2 agonist, siramesine. All four sigma-2 ligands
induced cell death in EMT-6 and MDA-MB-435 cells. Our results
indicated that (1) the apoptotic pathway is, in part, responsible
for cell death; (2) the sigma-2 ligands induced autophagy; and
(3) the sigma-2 ligands impaired cell-cycle progression.
We first examined whether the sigma-2 ligands induced cell
death through activating apoptosis. All three ligands induced
Annexin-V-positive cells (Supplementary Figure 1), DNA fragmentation, caspase-3 activation and PARP-1 cleavage. In addition,
at least one sigma-2 ligand, RHM-138, activated caspase-8 and
9 (Supplementary Figure 2). These results suggest that sigma-2
ligands induced apoptosis possibly through both intrinsic and
extrinsic pathways. This conclusion is consistent with that
reported from other laboratories (Crawford and Bowen, 2002;
Ostenfeld et al, 2005). Our data also showed that the broadspectrum caspase inhibitor, Z-VAD-FMK, partially inhibited DNA
fragmentation and cytotoxicity of the sigma-2 ligands, suggesting
that caspases are, in part, responsible for sigma-2 ligand (WC-26,
SV119 and RHM-138)-induced cell death in EMT-6 and MDA-MB435 cells. In previous studies, Crawford et al showed that the
caspase inhibitors had no effect on sigma-2 ligand (CB-64D and
CB-184) cytotoxicity or Annexin-V binding in human breast
MCF-7 cells (Crawford and Bowen, 2002). Ostenfeld et al (2005)
reported that caspase inhibitors failed to protect cells against
siramesine-induced death in murine fibrosarcoma cells (WEHI-S)
and MCF-7 cells. It appears that whether caspases are involved in
sigma-2-induced cell death depends on the structure of the ligand,
ligand concentration and tumour cell type.
British Journal of Cancer (2012) 106(4), 693 – 701
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Figure 4 WC-26 and siramesine induced the formation of autophagosomes in MDA-MB-435 cells studied by transmission electron microscopy. (A) Cells
without any treatment showed normal mitochondria ultrastructure (arrows). (B) Treatment with 100 mM WC-26 for 4 h induced mitochondrial swelling
(indicated by 1), multilayer membrane compartments containing mitochondria and other cytoplasm contents (indicated by 2), and various kinds of multilayer
membrane structures (indicated by 3). (C) Treatment with 100 mM WC-26 for 8 h induced autophagic vacuoles (indicated by 1) and mitochondrial swelling
(indicated by 2). (D) Treatment with 10 mM siramesine for 16 h induced the formation of various vacuoles.
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Figure 5 Sigma-2 ligands induced autophagy in MDA-MB-435 cells. Cells were treated with WC-26 (100 mM), SV119 (100 mM), RHM-138 (40 mM) or
siramesine (10 mM) for 0 – 24 h. Autophagosome markers, LC3B and the downstream effectors of mTOR, p70S6K and 4EBP1, were analysed by western
blotting.

We examined whether sigma-2 ligands induced autophagy.
Electron microscopic data showed that the sigma-2 ligands WC-26
and siramesine induced mitochondrial swelling and formation of
multilayer membrane vacuoles (Figure 4A – D). The sigma-2
ligands also increased the expression of the autophagosome
marker LC3B, and decreased the downstream effectors of mTOR,
p70S6K and 4EBP1 (Figure 5). These results suggest that sigma-2
ligands induce autophagy most likely by inhibiting the mTOR
pathway. These data are consistent with the previous report that
siramesine induced autophagosome formation in MCF-7 cells
(Ostenfeld et al, 2008). Autophagy has a dual role in cell survival
and cell death. On one hand, autophagy is generally thought of as a
survival mechanism through removal misfolded proteins and
damaged organelles. On the other hand, excess levels of autophagy
may lead to cell death (Platini et al, 2010). Ostenfeld et al (2008)
British Journal of Cancer (2012) 106(4), 693 – 701

showed that 3-methyladenine, an autophagy inhibitor, increased
cytotoxicity induced by siramesine. They also showed that
inhibition of autophagy by RNA interference-based depletion of
the autophagy protein beclin 1 increased cell toxicity of
siramesine. These data suggest that siramesine-induced autophagy
is cytoprotective in MCF-7 cells and NIH3T3 cells. Studies of a
variety of experimental systems indicate that whether autophagy is
cytoprotective or cytotoxic is likely to be context- and cell typedependent (Platini et al, 2010). The role of our sigma-2 ligands,
WC-26, SV119 and RHM-138, in autophagy in MDA-MB-435 cells
needs to be further studied.
In the current work, we studied the effects of sigma-2 ligands on
cell-cycle progression by examining the protein levels of the four
major classes of cyclins. Our data showed that sigma-2 ligands
altered cyclin protein expression levels and the phosphorylation
& 2012 Cancer Research UK
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Figure 6 Sigma-2 ligands impaired cell-cycle progression in MDA-MB-435 cells. Cells were treated with WC-26 (100 mM), SV119 (100 mM), RHM-138
(40 mM) or siramesine (10 mM) for 0 – 24 h. The expression levels of cyclin D1, pRb, cyclin E2, cyclin A and cyclin B1were analysed by western blotting.

levels of Rb (Figure 6). These data suggest that sigma-2 ligands
may induce cell death by impairing cell-cycle progression.
Regulation of cyclin levels has been extensively studied. Cyclin
D1 protein is subject to transcriptional regulation and ubiquitinmediated proteolysis (Witzel et al, 2010). Unlike other cyclins,
cyclin D1 is strongly dependent on extracellular mitogenic signals.
For example, cyclin D1 is induced by the Ras-signalling pathway
(Malumbres and Barbacid, 2001). It is possible that sigma-2
ligands decrease cyclin D1 by inhibiting the mitogenic signalling
pathways or/and by increasing ubiquitin-dependent degradation
processes. The Rb represses transcription by binding to transcription factors such as E2F-family members. D-type cyclins in
complexes with CDK4 and/or CDK6 result in phosphorylation of
Rb (Malumbres and Barbacid, 2005). This liberates E2F transcription factors and promotes the subsequent transcription of many
important proteins such as cyclin E. In the present study, we show
that the phosphorylation levels of Rb are decreased by WC-26,
SV119 and siramesine. This could result from cyclin D1 reduction
upon treatment with these ligands. The E-type cyclins are
regulated transcriptionally by the phosphorylation status of Rb
as well as by ubiquitin-dependent degradation mechanisms
(Musgrove, 2006; Caldon and Musgrove, 2010). Our data show
that WC-26 and SV119 decrease cyclin E2. This is probably due to
reduction of phospho-Rb. By contrast, siramesine does not reduce
cyclin E2. One possible reason is that siramesine decreases cyclin
E2 by reducing phospho-Rb, but at the same time increases cyclin
E2 by inhibiting its degradation. The net result is no change of
cyclin E2 expression. A- and B-type cyclins are also regulated at
the transcriptional level and by ubiquitin-mediated proteolysis
(Miyazaki and Arai, 2007). The current study shows that WC-26,
SV119 and siramesine caused a dramatic decrease in cyclin B1
expression. This could result from decreasing the transcription
and/or increasing the ubiquitin-dependent degradation processes.
& 2012 Cancer Research UK

Taking these data together, the sigma-2 ligands decrease multiple
cyclin protein levels. Decreasing cyclin levels has been proposed
as a therapeutic strategy for cancer treatment (Freemantle
et al, 2007). Our findings suggest that the sigma-2 ligands may
serve as promising antitumour drugs by disrupting cell-cycle
progression.
Sigma-2 ligands induce apoptosis, autophagy and cell-cycle
impairment. These pathways are inter-related. Autophagy and cellcycle arrest are known adaptive responses of cells to toxic insults
(Clarke and Allan, 2009; Wyllie, 2010). Cells can remove the
misfolded proteins and damaged organelles by autophagy. Cells
can also activate cell-cycle checkpoints, which provide an
opportunity to repair the damage. It is possible that upon sigma2 ligand treatment, cells initiate autophagy and cell-cycle arrest to
protect themselves from the toxic effects of the ligands. After these
mechanisms fail to rescue the cells, they switch to facilitate cell
death. Understanding the turning points where adaptive responses
become contributors to toxicity is important for designing
effective cancer therapeutic interventions. The PI3K/Akt/mTOR
pathway is well known as one of the key molecular switches
between apoptosis and autophagy (Moretti et al, 2007; Wyllie,
2010; Li et al, 2011). Our data suggest that sigma-2 ligands increase
autophagy and apoptosis by suppressing the mTOR pathway.
In addition, recent studies have revealed that the cell-cycle
components can be directly involved in apoptosis. It is reported
that CDK1 – cyclin B1 is a crucial regulator of not only mitosis but
also apoptosis (Clarke and Allan, 2009). Cyclin-dependent kinase1 – cyclin B1 phosphorylates the inhibitory site on caspase-9
(Thr125) during mitosis (Allan and Clarke, 2007). Phosphorylation
of this site restrains caspase-9 activation and apoptosis. It is
possible that the decrease in cyclin B1 upon treatment of the
sigma-2 ligands reduces the phosphorylation level of caspase-9 at
the inhibitory site and thus activates caspase-9 and apoptosis.
British Journal of Cancer (2012) 106(4), 693 – 701
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Previously we have shown that the sigma-2 fluorescent ligands
rapidly internalise into cells and localise in the mitochondria,
lysosomes, endoplasmic reticulum and plasma membranes (Zeng
et al, 2007, 2011). It is possible that sigma-2 ligands trigger
multiple signalling pathways by binding to sigma-2 receptors
located in multiple cytoplasmic organelles and plasma membranes.
For example, sigma-2 ligands may bind to mitochondria and
damage their structure and function, as shown by mitochondrial
swelling (Figure 4B and C), and trigger caspase-3-dependent or independent apoptosis (Crawford and Bowen, 2002; Ostenfeld
et al, 2005). Sigma-2 ligands may bind to lysosomes, and cause
lysosomal leakage and cell death as demonstrated previously
by Ostenfeld et al (2005). The damage to cytoplasmic organelles by
sigma-2 ligands may trigger autophagy, which may have either a
survival or a detrimental role depending on the structure of the
drugs and the tumour cell type.
Positron emission tomography imaging in rodent (Mach et al,
2001a; Kawamura et al, 2003) and human studies (unpublished
data) has demonstrated that sigma-2 ligands selectively target
tumours in vivo. Sigma-2 receptor ligands have shown efficacy in

various tumour cells using cell culture and animal models
(Ostenfeld et al, 2005; Kashiwagi et al, 2007, 2009) by multiple
signalling pathways. These characteristics make sigma-2 ligands
promising chemotherapeutic drugs for treating a variety of
tumours.
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